TAS-102

Identification

Logo pink
Are you a
new drug developer?
Contact us to learn more about our customized products and solutions.
Name
TAS-102
Accession Number
DB08937
Type
Small Molecule
Groups
Investigational
Description

TAS-102 (Taiho Pharma USA, Inc.) is an anti-cancer drug under development and in stage 3 clinical trials for the treatment of colorectal cancer. It is composed of the thymidine phosphorylase inhibitor (TPI) tipiracil and the cytotoxin trifluridine. Trifluridine inhibits tumor growth by being incorporated into DNA during DNA synthesis. Tipiracil prevents trifluridine from being broken down when taken orally.

Synonyms
Not Available
Categories
UNII
Not Available
CAS number
733030-01-8
Weight
Not Available
Chemical Formula
Not Available
InChI Key
Not Available
InChI
Not Available
IUPAC Name
Not Available
SMILES
Not Available

Pharmacology

Indication
Not Available
Pharmacodynamics
Not Available
Mechanism of action
Not Available
Additional Data Available
Adverse Effects

Comprehensive structured data on known drug adverse effects with statistical prevalence. MedDRA and ICD10 ids are provided for adverse effect conditions and symptoms.

Learn more
Additional Data Available
Contraindications

Structured data covering drug contraindications. Each contraindication describes a scenario in which the drug is not to be used. Includes restrictions on co-administration, contraindicated populations, and more.

Learn more
Additional Data Available
Blackbox Warnings

Structured data representing warnings from the black box section of drug labels. These warnings cover important and dangerous risks, contraindications, or adverse effects.

Learn more
Absorption
Not Available
Volume of distribution
Not Available
Protein binding
Not Available
Metabolism
Not Available
Route of elimination
Not Available
Half life
Not Available
Clearance
Not Available
Toxicity
Not Available
Affected organisms
  • Humans and other mammals
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
Not Available
Food Interactions
Not Available

References

General References
  1. Emura T, Suzuki N, Yamaguchi M, Ohshimo H, Fukushima M: A novel combination antimetabolite, TAS-102, exhibits antitumor activity in FU-resistant human cancer cells through a mechanism involving FTD incorporation in DNA. Int J Oncol. 2004 Sep;25(3):571-8. [PubMed:15289858]
  2. Link [Link]
External Links
PubChem Substance
347910389
Wikipedia
TAS-102

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
1CompletedTreatmentAdvanced Gastrointestinal Tumors1
1CompletedTreatmentAdvanced Solid Tumors3
1CompletedTreatmentAdvanced Solid Tumors (Excluding Breast Cancer)2
1CompletedTreatmentAdvanced or Metastatic Solid Tumors1
1Not Yet RecruitingTreatmentRefractory Solid Tumors1
1RecruitingTreatmentAdvanced Solid Tumors1
1RecruitingTreatmentHepatic Metastases / Malignant Neoplasm of Colon / Rectal Carcinoma1
1RecruitingTreatmentMalignancies / Neoplasms / Neuroendocrine Tumors / Tumors1
1RecruitingTreatmentRAS Family Gene Mutation / Stage III Colon Cancer AJCC v7 / Stage III Colorectal Cancer AJCC v7 / Stage III Rectal Cancer AJCC v7 / Stage IIIA Colon Cancer AJCC v7 / Stage IIIA Colorectal Cancer AJCC v7 / Stage IIIA Rectal Cancer AJCC v7 / Stage IIIB Colon Cancer AJCC v7 / Stage IIIB Colorectal Cancer AJCC v7 / Stage IIIB Rectal Cancer AJCC v7 / Stage IIIC Colon Cancer AJCC v7 / Stage IIIC Colorectal Cancer AJCC v7 / Stage IIIC Rectal Cancer AJCC v7 / Stage IV Colon Cancer AJCC v7 / Stage IV Colorectal Cancer AJCC v7 / Stage IV Rectal Cancer AJCC v7 / Stage IVA Colon Cancer AJCC v7 / Stage IVA Colorectal Cancer AJCC v7 / Stage IVA Rectal Cancer AJCC v7 / Stage IVB Colon Cancer AJCC v7 / Stage IVB Colorectal Cancer AJCC v7 / Stage IVB Rectal Cancer AJCC v71
1RecruitingTreatmentRectal Adenocarcinoma / Recurrent Rectal Carcinoma / Stage IV Rectal Cancer AJCC v7 / Stage IVA Rectal Cancer AJCC v7 / Stage IVB Rectal Cancer AJCC v71
1, 2CompletedTreatmentColorectal Cancers1
1, 2RecruitingTreatmentAdvanced Gastric Cancer / Colorectal Adenocarcinoma / Gastric Adenocarcinoma / Non-Resectable Cholangiocarcinoma / Pancreatic Adenocarcinoma Metastatic / Stage IV Colorectal Cancer / Stage IV Pancreatic Cancer / Stage IVA Colorectal Cancer / Stage IVB Colorectal Cancer / Unresectable Pancreatic Carcinoma1
1, 2RecruitingTreatmentColorectal Cancers1
2Active Not RecruitingTreatmentPreviously Treated Metastatic Colorectal Cancer1
2Active Not RecruitingTreatmentSquamous Cell Lung Carcinoma1
2CompletedTreatmentRefractory, metastatic Colorectal cancer1
2RecruitingTreatmentMalignant Neoplasm of Pancreas1
2RecruitingTreatmentRefractory Colorectal Carcinoma / Stage III Colorectal Cancer AJCC v8 / Stage IIIA Colorectal Cancer AJCC v8 / Stage IIIB Colorectal Cancer AJCC v8 / Stage IIIC Colorectal Cancer AJCC v8 / Stage IV Colorectal Cancer AJCC v8 / Stage IVA Colorectal Cancer AJCC v8 / Stage IVB Colorectal Cancer AJCC v8 / Stage IVC Colorectal Cancer AJCC v81
2SuspendedTreatmentCholangiocarcinomas / Stage III Gallbladder Cancer AJCC V7 / Stage IIIA Gallbladder Cancer AJCC v7 / Stage IIIB Gallbladder Cancer AJCC v7 / Stage IV Gallbladder Cancer AJCC v7 / Stage IVA Gallbladder Cancer AJCC v7 / Stage IVB Gallbladder Cancer AJCC v71
2TerminatedTreatmentLung Cancer Small Cell Lung Cancer (SCLC)1
2TerminatedTreatmentMetastatic Colorectal Cancers1
2, 3CompletedTreatmentMetastatic Colorectal Cancers1
2, 3Not Yet RecruitingTreatmentColorectal Cancers / Metastasis1
3CompletedTreatmentColorectal Cancers2
3CompletedTreatmentRefractory Metastatic Gastric Cancer1
3WithdrawnTreatmentCarcinoma NOS / Metastatic Colorectal Cancers1
Not AvailableApproved for MarketingNot AvailableMetastatic Colorectal Cancers1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage forms
Not Available
Prices
Not Available
Patents
Not Available

Properties

State
Solid
Experimental Properties
Not Available
Predicted Properties
Not Available
Predicted ADMET features
Not Available

Spectra

Mass Spec (NIST)
Not Available
Spectra
Not Available

Taxonomy

Classification
Not classified

Drug created on March 07, 2014 10:52 / Updated on May 01, 2019 10:47